Back to List
Module 10 Views

Module 1 (US) — Administrative Forms (OBX-319)

July 12, 2026

📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪
Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄
About this document — a plain-language guide

What it is. Module 1 (US) — Administrative Forms (OBX-319)

Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.

How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.

Format & governing standard.


Module 1 (US) — Administrative Forms (OBX-319)

Document ID: M1-FORMS
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): 21 CFR 314/601

Administrative Forms — OBX-319

The regional administrative forms accompanying the OBX-319 application (Virtual Biopharma Inc.). Values are administrative placeholders in this mock; identifiers assigned by the authority at filing are shown as 'to be assigned'.

FormPurpose
FDA 1571Investigational New Drug Application
FDA 1572Statement of Investigator
FDA 356hApplication to Market a Biologic (BLA)
FDA 3454/3455Certification/Disclosure — Financial Interests of Investigators
FDA 3542/3542aPatent Information
FDA 3397User Fee Cover Sheet (PDUFA)
FDA 3674Certification of Compliance (ClinicalTrials.gov)
Debarment certification21 U.S.C. 335a certification
Field copy certificationCertification of the field copy
Letters of AuthorizationCross-reference to Biologics/Drug Master Files

21 CFR 601 (BLA); eCTD US regional 1.1-1.4.

Comments (0)

No comments yet. Be the first to say something!